LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
31 funds hold it · Insiders net selling
Net selling: insiders sold $5M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 4, 2026
Financial period
Q4 fiscal 2026
Earnings per share
$4.57 expected
Revenue
$87.91B expected
Estimates as of Nov 10, 2026
EPS expected
$4.53 to $4.58
Revenue expected
6 analysts
Last 30 days
Split both ways
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 4, 2026 | $4.66est. $4.57 | +1.88%beat | $88.40Best. $87.91B+0.56% | +5.6%from $83.73B |
| Jun 30, 2026Reported Aug 5, 2026 | $4.48est. $4.35 | +3.04%beat | $84.80Best. $84.15B+0.77% | +5.1%from $80.66B |
| Mar 31, 2026Reported May 6, 2026 | $4.75est. $4.72 | +0.65%in line | $78.36BSEC filing | +3.8%from $75.45B |
| Dec 31, 2025Reported Feb 4, 2026 | $4.08est. $4.04 | +0.99%in line | $85.93BSEC filing | +5.5%from $81.49B |
| Sep 30, 2025Reported Nov 5, 2025 | $3.84est. $3.79 | +1.32%beat | $83.73BAlpha Vantage | +5.9%from $79.05B |
| Jun 30, 2025Reported Aug 6, 2025 | $4.00est. $3.84 | +4.17%beat | $80.66BSEC filing | +8.7%from $74.24B |
| Mar 31, 2025Reported May 7, 2025 | $4.42est. $4.10 | +7.80%beat | $75.45BSEC filing | +10.3%from $68.41B |
| Dec 31, 2024Reported Feb 5, 2025 | $3.73est. $3.52 | +5.97%beat | $81.49BSEC filing | +12.8%from $72.25B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $83.73B | $85.93B | $78.36B | $84.75B |
| Cost of what it sold | $81.13B | $83.12B | $75.03B | $81.15B |
| Gross profit | $2.60B | $2.81B | $3.32B | $3.61B |
| What it spent | ||||
| Sales and admin | $1.75B | $1.80B | $1.98B | $2.13B |
| Other operating costs | — | — | — | $354.6M |
| Total operating expenses | $1.75B | $1.80B | $1.98B | $2.49B |
| What was left | ||||
| Operating profit | $854.6M | $1.02B | $1.34B | $1.12B |
| Interest on debt | $109.4M | $93.4M | $154.3M | $140.7M |
| Profit before tax | -$187.0M | $708.6M | $2.09B | $996.4M |
| Tax | $146.0M | $142.5M | $459.0M | $219.7M |
| Net profit | -$339.7M | $559.6M | $1.64B | $763.5M |
| EBITDA | $183.3M | $1.04B | $2.50B | $1.42B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Form 4 Cencora, Inc. For: Nov 06 Filed by: Campbell Elizabeth S
NeutralNov 10Cencora stock enters fiscal 2027 with specialty-led growth outlook
NeutralNov 10DataMEDS Completes First Compounded Peptide Sale
Leans bullishNov 9Cencora, Inc. (COR) latest stock news and headlines
NeutralNov 9Cardinal Health (CAH) Lifts Guidance As Investors Ask If The Story Is Fully Valued
NeutralNov 7Cencora stock enters fiscal 2027 with stronger earnings outlook
BullishNov 7Cencora, Inc. (COR) Seasonal returns chart
NeutralNov 6Cencora, Inc. (COR) Seasonal Returns Chart - Yahoo Finance
NeutralNov 634 macro signals shaping COR right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
